Pancreatic Islet and Stellate Cells Are the Main Sources of Endocrine Gland-Derived Vascular Endothelial Growth Factor/Prokineticin-1 in Pancreatic Cancer

https://doi.org/10.1159/000178888Get rights and content

Abstract

Aims: Endocrine gland-derived vascular endothelial growth factor (EG-VEGF)/prokineticins have been identified as tissue-specific angiogenic factors. This study investigates the expression and localization of EG-VEGF and its receptors in pancreatic tissues and pancreatic stellate cells (PSCs). Methods: mRNA levels of EG-VEGF/prokineticin 1 (PK1), prokineticin 2 (PK2) and their receptors 1 (PKR1) and 2 (PKR2) were measured in pancreatic tissues, pancreatic cancer cell lines and PSCs by quantitative reverse-transcriptase polymerase chain reaction (QRT-PCR). Protein expression of PKI, PKR1 and PKR2 was assessed in pancreatic tissues by immunohistochemistry. Growth factor-induced secretion of EG-VEGF was measured by ELISA. Results: QRT-PCR analysis in bulk tissues of normal pancreas, chronic pancreatitis and pancreatic ductal adenocarcinoma showed no significant difference of PK1 mRNA levels, whereas PK2 mRNA was barely detectable. High PK1 mRNA levels were observed only in cultured PSCs and microdissected islet cells, but not in cancer cells, and PK1 protein was localized mainly in islets and cancer-associated stromal cells. PKR1 and PKR2 proteins were present in endothelial cells of small blood vessels. TGF-β1 and PDGF-BB specifically stimulated PK1 secretion in PSCs. Conclusions: Islet and/or PSC-derived PK1 might act through its receptors on endothelial cells to increase angiogenesis in pancreatic diseases.

References (35)

  • G Bergers et al.

    Tumorigenesis and the angiogenic switch

    Nat Rev Cancer

    (2003)
  • MW Saif

    Anti-angiogenesis therapy in pancreatic carcinoma

    JOP

    (2006)
  • A Abdollahi et al.

    Transcriptional network governing the angiogenic switch in human pancreatic cancer

    Proc Natl Acad Sci USA

    (2007)
  • AM Byrne et al.

    Angiogenic and cell survival functions of vascular endothelial growth factor

    J Cell Mol Med

    (2005)
  • SM Weis et al.

    Pathophysiological consequences of VEGF-induced vascular permeability

    Nature

    (2005)
  • N Ferrara et al.

    Clinical applications of angiogenic growth factors and their inhibitors

    Nat Med

    (1999)
  • J LeCouter et al.

    Identification of an angiogenic mitogen selective for endocrine gland endothelium

    Nature

    (2001)
  • Cited by (39)

    • Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ductal adenocarcinoma

      2020, Pancreatology
      Citation Excerpt :

      Platelet-derived growth factor (PDGF) from the stellate cells induces cancer cell proliferation and aids migration of more stellate cells to the tumor in a feed-forward loop [27]. They stimulate angiogenesis via VEGF release, aiding the growth of the tumor [28] and potentially increasing CAR T cell perfusion into the TME. However, contrastingly, VEGF can play an immunosuppressive role in the TME by inducing inhibitory checkpoints such as PD-1 in CD8+ T cells and can thus render CAR T cells ineffective [29,30].

    • EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway

      2019, Biomedicine and Pharmacotherapy
      Citation Excerpt :

      Most of EG-VEGF exists in endocrine steroid organs, including ovaries, testes, adrenal glands, and placenta, and is closely related to the occurrence and development of various specific tissue tumors [4–6]. Much evidence suggests that EG-VEGF is distributed diffusely in PC tissues and its positive expression rate is up to 95% [7,8], suggesting a correlation between EG-VEGF and PC progression. EG-VEGF has two receptors, PKR1 (prokineticin receptor 1) and PKR2 (prokineticin receptor 2), which can be coupled with Gq, Gs or Gi protein.

    • Galectin-1-driven upregulation of SDF-1 in pancreatic stellate cells promotes pancreatic cancer metastasis

      2017, Cancer Letters
      Citation Excerpt :

      Galectin-1 is involved in a wide range of biological activities including apoptosis, migration, adhesion, malignant transformation, carcinogenesis, tumor angiogenesis, and immunosuppression [23,31–37]. Pancreatic tumor cells have been found to stimulate PSCs to express enhanced levels of Galectin-1 by secreting cytokine transforming growth factor TGF-β1 [20,38]; this in turn induced activation and proliferation of PSCs resulting in a cycle that sustained the stromal reaction and promoted the malignant behavior of PDAC [21,39,40]. We previously demonstrated that Galectin-1 was overexpressed in PSCs leading to the formation of fibroblasts surrounding the tumor cells and was associated with perineural invasion, advanced tumor stage, lower differentiation and poor prognosis in patients with pancreatic cancer [16,20,41].

    View all citing articles on Scopus
    1

    Jörg Kleeff, MD Department of Surgery, Technische Universität München Ismaningerstrasse 22, DE-81675 Munich (Germany) Tel. +49 89 4140 5098, Fax +49 89 4140 4870

    View full text